The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials...
Recognition of Continued Growth Comes as Company Celebrates its 15th AnniversaryTOWSON, Md., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Vistant, a...
- AB126 is an unmodified exosome derived from neural stem cells with the innate ability to cross the blood-brain-barrier and...
LAS VEGAS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Dr. Jack Jacobs, Chief Science Officer of Zhittya Genesis Medicine, Inc. (a...
NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative...
DENVER, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
TAMPA, Fla., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Nextech, a complete healthcare technology solution for specialty providers, announced today the...
Non-profit to Kick Off Back-to-School Campaign with a Times Square Billboard on National Non-Profit Day CYCLE Kids A Bike Can...
-Clinical outcomes presented at Military Health System Research Symposium (MHSRS)- -Results will be included in Biologics License Application (BLA) planned...
NEW YORK and LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading...
FORT WORTH, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Carhartt Inc., one of America’s leading manufacturers of durable workwear and...
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients...
Announces next steps for clinical development plan in severe liver diseasesBOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:...
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a...
The combined Company is projected to generate more than $25 million in gross revenue in 2024 and be cashflow positive...
MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or...
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE...
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyTrial to...
Tampa, FL, Aug. 15, 2023 (GLOBE NEWSWIRE) -- DAS Health, a leading provider of health IT and management solutions, is...